Abstract：Objective: To observe the safety and efficacy through the application of autologous NK cells in MMASCT transplantation. Methods: 8 cases of MM patients, including 7 males and 1 female, aged 42-62 years, the median age of 51 years, before transplantation CR2 cases, PR6 cases. NK cell culture method: Membrane chimeric activity factor culture system. The pretreatment program is based on the standard melphalan or Baihuaan or fludarabine-based regimen. Two of the NK cells were transfused 6-7 days after stem cell infusion, and six of the NK cells were used as part of the transplant pretreatment program, 48 hours after chemotherapy and 24 to 48 hours before the stem cell was returned. Stem cell infusion: CD34 + cells 2.2-4.0x10 ^ 6 / kg, mononuclear cells 4.3-5.8x10 ^ 8 / kg. NK cell infusion: 16-160 * 10 ^ 6 / kg. Observe the adverse reactions, blood cell recovery time and efficacy .Results: 8 cases of fever in 6 patients, body temperature 38-39 degrees, the clinical consideration of lung infection, 1 case of oral mucositis (grade II), anti-infection symptomatic treatment after remission, no rash, diarrhea and other adverse reactions The recovery time of hematopoietic cells were as follows: granulocyte (more than 0.5 * 10 ^ 9 / L continuous 3d) 7-14d, median time 9 days, platelet (greater than 30 * 10 ^ 9 / L continuous 3d) 9-34 days Bit time 11 days. 8 patients were successfully completed ASCT. 3 months after transplantation, 3 cases of CR, 5 cases of PR. Eight patients were given thalidomide maintenance therapy. The follow-up period was 3 to 29 months, with a median follow-up of 11 months and no deaths during follow-up. Conclusion: Autologous NK cells in the MMASCT transplantation during the application, no inflammatory factor storm effect occurs, return safety, the treatment is effective. To further expand the number of cases of clinical studies to observe its long-term adverse reactions and efficacy.
[1] 李倩,李晓明.多发性骨髓瘤的临床治疗研究新进展[J].西南军医,2011,12(4):690~693. [2] 张天弼,廖建军.多发性骨髓瘤117例分析[J].中国基层医药,2006,13(6):1018~1019. [3] 郭丽堃,黎民君,罗华山,钟樱红,冯思琼.T-VAD与VAD方案治疗多发性骨髓瘤的疗效对比观察[J].河北医学,2013,19(1):18~20. [4] 郭丽堃,黎民君,罗华山,等.T-VAD与VAD方案治疗多发性骨髓瘤的疗效对比观察[J].河北医学,2013,19(1):17~20. [5] 胡十齐,周新伏,罗自勉.多发性骨髓瘤患者预后相关因素分析[J].河北医学,2012,18(6):763~767. [6] 粟小莲.多发性骨髓瘤30例临床分析[J].中国基层医药,2006,13(10):1677. [7] 胡十齐,周新伏,罗自勉.多发性骨髓瘤患者预后相关因素分析[J].河北医学,2012,18(6):763~767. [8] 高广义.多发性骨髓瘤32例临床特征分析[J].中国基层医药,2007,13(10):1703~1704. [9] Attal M, Harousseau J L. The role of high-dose therapy with autologous stem cell support in the era of novel agents[J].Seminars in hematology. WB Saunders, 2009, 46(2): 127~132. [10] Lenhoff S, Hjorth M, Turesson I, et al. Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation[J].Haematologica, 2006, 91(9): 1228~1233. [11] Child J A, Morgan G J, Davies F E, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma[J].New England Journal of Medicine, 2003, 348(19): 1875~1883. [12] Alegre A, Granda A, Martinez-Chamorro C, et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry[J].haematologica, 2002, 87(6): 609~614. [13] Facon T, Mary J Y, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial[J].The Lancet, 2007, 370(9594): 1209~1218. [14] Kumar L1, Boya RR1, Pai R1,et al. Autologous stem cell transplantation for multiple myeloma: Long-term results[J].Natl Med India. 2016;29(4):192~199. [15] Murphy W J, Koh C Y, Raziuddin A, et al. Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies[J].Immunological reviews, 2001, 181(1): 279~289. [16] Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation[J].Blood, 1999, 94(1): 333~339. [17] Krre K. A perfect mismatch[J].Science, 2002, 295(5562): 2029~2031. [18] Harrison S J, Cook G. Immunotherapy in multiple myeloma–possibility or probability[J].British journal of haematology, 2005, 130(3): 344~362. [19] Frohn C, Hppner M, Schlenke P, et al. Anti‐myeloma activity of natural killer lymphocytes[J].British journal of haematology, 2002, 119(3): 660~664.
2017, Vol. 23 
冀公网安备13080202000677号